Lee, Tae Hoon http://orcid.org/0000-0002-4723-3931
Chang, Ji Hyun http://orcid.org/0000-0001-5921-5522
Jang, Bum-Sup http://orcid.org/0000-0002-7064-9855
Kim, Jae Sik http://orcid.org/0000-0002-0039-8667
Kim, Tae Hyun http://orcid.org/0000-0001-8413-3385
Park, Won http://orcid.org/0000-0003-4686-2071
Kim, Yong Bae http://orcid.org/0000-0003-4884-2330
Kim, Su Ssan http://orcid.org/0000-0002-8473-302X
Han, Wonshik http://orcid.org/0000-0001-7310-0764
Lee, Han-Byoel http://orcid.org/0000-0003-0152-575X
Shin, Kyung Hwan http://orcid.org/0000-0002-5852-7644
Article History
Received: 22 September 2022
Accepted: 3 November 2022
First Online: 16 November 2022
Declarations
:
: Protocol of the PORT-N1 trial was approved by Institutional Review Board of Seoul National University Hospital (number H-2205-167-1328). Protocol version 1.0 was approved on June 27, 2022. All clinical treatments are conducted in accordance to International Good Clinical Practice Guidelines and the Declaration of Helsinki. Written consent is obtained from each participant before enrollment. Participants are aware of the purpose, potential advantages, and risks of the trial.
: Not applicable.
: The authors declare that they have no competing interests.